semaglutide formulary A higher-dose of Wegovy has received final regulatory clearance in the EU, marking a significant step for obesity treatment. The approval allows physicians to prescribe a weekly 7.2 mg dose, administered as GLP-1 Scripts for Seniors? Expect

Semaglutide activates only GLP-1 receptors, while tirzepatide (a GLP-1/GIP receptor agonist) engages dual pathways, often producing faster or more substantial weight lossup to 22% in clinical trials versus 15% for semaglutide alone

Although rare, more serious side effects can occur

While GLP-1 (glucagon-like peptide-1) is a well-characterized incretin hormone, its therapeutic analogs present unique challenges in drug discovery and development

Semaglutide has been found to be safe for long-term use in managing type 2 diabetes for many individuals

This is counterproductive

Clinical trials show that diarrhea occurs in approximately 19-30% of patients using these medications for weight management